SlideShare une entreprise Scribd logo
1  sur  56
Télécharger pour lire hors ligne
Presented by
Nand Kishor Jha
 Basics Understanding of hypertension:
. Introduction
. Symptoms
.Types
. Risk factors
. Pathophysiology
. Classifications
. Causes & complications
. Work sheet /recap
• Treatment : Algorithm
• RAAS
• Antihypertensive drugs
• Compelling Indication for hypertensive drugs
• Diabetes and hypertension
• CVD risks in CKD
• Work sheet/recap
 A sustained elevation in arterial blood
pressure above the normal value is called
hypertension.
 Normal value for blood pressure varies
greatly from person to person.
• Tiredness
• Confusion
• Vision changes
• Angina-like chest pain
• Heart failure
• Blood in urine
• Bleeding nose
• Irregular heartbeat etc
. Primary hypertension: also called essential
hypertension, the cause of this type is unknown.
. Secondary hypertension: have specific identified
cause for elevated BP that due to any other medical problems
or medication.
. Pseudo hypertension: Osler’s sign of pseudo
hypertension, a falsely elevated BP regarding due to
calcification of blood vessel which can not be compressed.
. White coat hypertension: A syndrome whereby a
patient’s feeling of anxiety in a medical environment results
in an abnormally high reading when their blood pressure is
measured.
Hypertension
 There are two values for blood pressure in a
human being.
◦ Systolic blood pressure : Blood pressure
recorded during ventricular systole ( contraction
of ventricles).
◦ Diastolic blood pressure : Blood pressure
recorded during ventricular diastole ( relaxation
of ventricle) .
For the diagnosis blood pressure should be
measured at least on two separate occasions.
Continue….
Continue….
Continue….
Pathophysiology of hypertension:
Blood pressure = cardiac output x total
peripheral resistance
• Cardiac output = Hear rate X Stroke volume
(cardiac output: the amount of blood that the heart flows in a minute.
stroke volume: the amount of blood that heart flows during a cardiac cycle.
Cardiac cycle: the sequences of events that occurs when the heart beats)
 The National High Blood Pressure Education
Program presents the complete Seventh
Report of the Joint National Committee on
Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure.
 Table below provides a classification of BP
for adults aged 18 and older.
 The classification is based on the average of
2 or more properly measured, seated BP
readings on each of 2 or more office visits.
Category SBP (mm Hg) DBP (mm Hg)
Normal < 120 and < 80
Pre-hypertension 120-139 or 80-89
Hypertension, Stage-1 140-159 or 90-99
Hypertension, Stage-2 > 160 or > 100
Pt age SBP (mm Hg) DBP (mm Hg)
>/= 60 yrs < 150 and < 90
< 60 yrs < 140 and <90
< 60 yrs with CKD <140 and <90
< 60 yrs with DM <140 and < 90
Hypertension
 The prevalence of hypertension increases
with advancing age to point where more than
half people aged 60 to 69 years old and
approximately three fourths of those aged 70
years and older are affected.
 The age-related rise in SBP is primarily
responsible for an increase in both incidence
and prevalence of hypertension with
increasing age.
 95% of hypertensive patients have no
apparent identifiable cause, hence called
primary or essential hypertension.
 5% have some underlying cause to account
for the hypertension and called secondary
hypertension.
Renal: related to kidney disease
 Acute Renal Failure : Loss of function of
kidney over a short period of time.
 Chronic Renal Failure: failure of function of
kidney over a long time.
 Glomerulonephritis : ( inflammation of
glomerulus, a structural & functional unit of
kidney)
Endocrine system:
 Cushing Disease: It is a disorder caused by
high levels of cortisol (hormone ) in the
blood from a variety of causes, including
cancer of pituitary gland
 Hypothyroidism: low levels of thyroid
hormone
 Pheochromocytoma : It is a tumour (cancer )
that arises from the centre of the adrenal
gland
 Primary Hyperaldosteronism : increase
secretion of aldosterone
Renovascular
 Renal artery stenosis ( narrowing of arteries
of kidney)
Miscellaneous
 Pregnancy Induced hypertension
 Drug induced
Untreated hypertension can develop damage to
heart, kidney, retina and brain.
 Stroke : Sustained persistent high blood
pressure may lead to rupture of an artery in
the brain causing brain
haemorrhage/stroke ( bleeding )
 Retinopathy : Similarly it cause damage to
the blood vessels of retina and swelling of
retina which may lead to blindness.
 Nephropathy : Kidneys are also severely
damaged and ultimately may develop renal
failure (hypertensive nephropathy).
 Myocardial infarction : Accelerates
atherosclerosis, which may predispose to
development of blood clot in the artery
(thrombosis).Thrombosis in the brain or
heart ultimately causes brain infract or
myocardial infract (heart attack).
Summary :
Heart damage – MI,CHF
Kidney damage – nephropathy
Eye damage – retinopathy, loss of vision
Blood vessel damage – arteriosclerosis
Brain damage - stroke
Hypertension
 The relationship between BP and risk of CVD
events is continuous, consistent and
independent of other risk factors.
 Higher the BP, the greater is the chance of
heart attack, HF, stroke, and kidney disease.
Hypertension
 a) Systolic BP
 b ) Diastolic BP
 c) Pulse Pressure
 d) None of Above
Ans :
 a) Essential or Primary
 b) Secondary
 c) Malignant
 d) None of Above
Ans :
 a) Inconsistent
 b) Continuous
 c) Continuous, consistent & independent
 d) None of above
 a) <140/90
 b) > 140/90
 c) < 130/80
 d) None of above
Hypertension
Hypertension
 Kidney in response to low BP, reduced blood volume or low
sodium content release an enzyme, renin
 Renin interacts with angiotensinogen to form angiotensin I
 Angiotensin I gets converted to angiotensin II with the help of
ACE
 Angiotensin II causes aldesterone release from kedney,which
causes sodium and water retention leading to increase blood
volume.
 Similarly, angiotensin II causes vasoconstriction.
 These effects lead to increase in blood pressure.
 Weight reduction
 DASH (Dietary approach to stop hypertension)
eating plan: diet rich in fruits, vegetables, low
fat dairy products with a reduced content of
saturated and total fat
 Dietary sodium restriction
 Physical activity & Moderation of alcohol
consumption
Hypertension
ACE inhibitors : Enlapril, Ramipril etc.
 ACE inhibitors inhibit the conversion
of angiotensin I into angiotensin II by
inhibiting ACE ( Angiotensin
converting enzyme). They blunt the
effects mediated by angiotensin II (
like vasoconstriction , release of
aldosterone etc.)
β blockers : Metoprolol, Bisoprolol etc.
 β blockers act by reducing heart rate
and myocardial contractility by
blocking β1 receptors primarily in the
heart.
Angiotensin II receptor blockers(ARBs
): Losartan,Telmisartn, Olmesartan
etc.
 ARBs block the activation of
angiotensin II AT1 receptors.
Blockade of AT1 receptors directly
causes vasodilation, reduces
secretion of vasopressin, reduces
production and secretion of
aldosterone, amongst other actions –
the combined effect of which is
reduction of blood pressure.
Calcium channel blockers: Amlodipine, long acting
Nifedipine etc.
 Calcium channel blockers work by blocking
calcium channels in the heart and in the blood
vessels. This prevents calcium levels from
increasing as much in the cells when stimulated,
leading to less contraction.
α1 blockers like Prazosin, Terazosin etc.
 α1 blockers act by blocking the alpha1-receptors
of vascular smooth muscle, thus preventing the
uptake of catecholamine(harmones produced by
adrenal gland) by the smooth muscle cells.
 This causes vasodilatation and allows blood to flow
more easily.
Diuretics: Hydrochlorothiazide, Torsemide
etc.
 Diuretics act by enhanced urinary excretion
of sodium , chloride and water.
Aldosterone antagonists: Spironolactone,
Eplerenone etc.
 Aldosterone antagonists act by inhibits the
effect of aldosterone by competing for
intracellular aldosterone receptors the distal
tubule cells. This increases the secretion of
water and sodium, while decreasing the
excretion of potassium
 -adrenergic blockers and diuretics
 ACE inhibitors and diuretics
 Angiotensin II receptor antagonists and
diuretics
 Calcium antagonists and ACE inhibitors
 Other combinations
Compelling Indication : Initial therapy options
Heart Failure : THIAZ,BB,ACEI,ARB,ALDO ANT
Post myocardial infraction : BB,ACEI,ALDO ANT
High CVD risk : THIAZ,BB,ACEI,CCB
Diabetes : THIAZ,BB,ACEI,ARB,CCB
Chronic kidney disease : ACEI,ARB
Recurrent stroke prevention : THIAZ,ACEI
 Good therapeutic efficacy.
 Longer duration of action.
 Permitting once a day dosing.
 Cost effective.
 Minimal or no adverse effect.
 Minimal or no drug interaction.
 Should be safe in elderly patients.
 Should effectively reduces the
consequences of hypertension.
 Compelling indications: Hypertension may
exist in association with other conditions in
which there are compelling indications for
use of a particular treatment based on
clinical trial data demonstrating benefit of
such therapy.
 Example: hypertension associated diabetes
 In this case, ACEI or ARB should be used as
the first line therapy
 In this , the drug of first choice is either ACE
inhibitor or ARB (angiotensin receptor
blocker )
 Type 2 diabetes constitutes over 90% of
diabetes in the United States and is
associated with a 70% to 80% chance of
premature death from CVD and stroke.
 The concordance of hypertension and
diabetes is increased in the population;
hypertension is disproportionately higher in
diabetics while persons with elevated BP are
2.5 times more likely to develop diabetes
within 5 years
 The coexistence of hypertension in diabetes
is particularly pernicious because of the
strong linkage of the 2 conditions with all
CVD, stroke, progression of renal disease
and diabetic retinopathy.
 The United Kingdom Prospective Diabetes
Study (UKPDS) demonstrated that each 10
mm Hg decrease in SBP was associated with
average reductions in rates of diabetes-
related mortality of 15%; myocardial
infarction, 11%; and the microvascular
complications of retinopathy or
nephropathy, 13%.
 CVD is the most common cause of death in
individuals with CKD, and CKD is itself an
independent risk factor for CVD.
 The joint recommendations of the American
Society of Nephrology and the National
Kidney Foundation (NKF) provide useful
guidelines for management of hypertensive
patients with CKD.
 They recommend a goal BP for all CKD
patients of <_130/80 mm Hg and a need
for more than 1 antihypertensive drug to
achieve this goal.
 The guidelines indicate that most patients
with CKD should receive an ACEI or an ARB
in combination with a diuretic and that many
will require a loop diuretic( act at the
ascending limb of the loop of Henle in the
kidney) rather than a thiazide.
 In addition, if there is a conflict between the
goals of slowing progression of CKD and
CVD risk reduction, individual decision-
making is recommended, based on risk
stratification.
 An associated disease with hypertension
compels not to use a specific
antihypertensive drugs for treatment of
hypertension.
 For example: bronchial asthma with
hypertension is a compelling contraindication
for β blocker.
 It is not a curable but a controllable
disease
 Onset is generally at age of 40 or more.
 Has strong association with
atherosclerosis.
 Familial tendency is also known.
 If not treated, it goes on progressing.
 Untreated hypertension can develop
damage to heart, kidney, retina and brain.
 Treatment can prevent these complications.
Hypertension
 a) DASH Diet
 b) Weight reduction
 c) Physical activity
 d) All above
Ans :
 a) Calcium channel blockers
 b) ACEI
 c) ARB
 d) b & c
Ans :
 a) Calcium channel blockers
 b) ARBs
 c) Non-selective 1 –blockers
 d) None of above
Hypertension

Contenu connexe

Tendances (20)

Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Management of hypertensive crisis
Management of hypertensive crisisManagement of hypertensive crisis
Management of hypertensive crisis
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension 2020 Updated Guidelines
Hypertension 2020 Updated GuidelinesHypertension 2020 Updated Guidelines
Hypertension 2020 Updated Guidelines
 
HYPERTENSION
HYPERTENSIONHYPERTENSION
HYPERTENSION
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension management 2018
Hypertension management  2018Hypertension management  2018
Hypertension management 2018
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
Hypertension Hypertension
Hypertension
 
Management of hypertension in diabetes
Management of hypertension in diabetesManagement of hypertension in diabetes
Management of hypertension in diabetes
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
world Hypertension day 2023.pdf
world Hypertension  day 2023.pdfworld Hypertension  day 2023.pdf
world Hypertension day 2023.pdf
 
Hypertension
HypertensionHypertension
Hypertension
 

Similaire à Hypertension

1. Hypertension (2).pptx
1. Hypertension (2).pptx1. Hypertension (2).pptx
1. Hypertension (2).pptxsamsonkiflu
 
Essential hypertension management and treatment
Essential hypertension management  and treatmentEssential hypertension management  and treatment
Essential hypertension management and treatmentFabio Grubba
 
hypertension-definition,causes,diagnosis.pptx
hypertension-definition,causes,diagnosis.pptxhypertension-definition,causes,diagnosis.pptx
hypertension-definition,causes,diagnosis.pptxWILLIAM485410
 
Hypertension llb explains by harrionsion book
Hypertension llb explains by harrionsion bookHypertension llb explains by harrionsion book
Hypertension llb explains by harrionsion booknxrg25985g
 
Hypertension presentation
Hypertension presentationHypertension presentation
Hypertension presentationTeketel23
 
hypertension-161006095542.pptx
hypertension-161006095542.pptxhypertension-161006095542.pptx
hypertension-161006095542.pptxDavudAhmedzade
 
Blood pressure regulation
Blood pressure regulationBlood pressure regulation
Blood pressure regulationNAKULBK1
 

Similaire à Hypertension (20)

Presentation1 (8).pptx
Presentation1 (8).pptxPresentation1 (8).pptx
Presentation1 (8).pptx
 
Hypertension
HypertensionHypertension
Hypertension
 
1. Hypertension (2).pptx
1. Hypertension (2).pptx1. Hypertension (2).pptx
1. Hypertension (2).pptx
 
Essential hypertension management and treatment
Essential hypertension management  and treatmentEssential hypertension management  and treatment
Essential hypertension management and treatment
 
hypertension.docx
hypertension.docxhypertension.docx
hypertension.docx
 
10 hypertension
10 hypertension10 hypertension
10 hypertension
 
hypertension.pptx
hypertension.pptxhypertension.pptx
hypertension.pptx
 
hypertension-definition,causes,diagnosis.pptx
hypertension-definition,causes,diagnosis.pptxhypertension-definition,causes,diagnosis.pptx
hypertension-definition,causes,diagnosis.pptx
 
Hypertension
Hypertension Hypertension
Hypertension
 
Hypertension llb explains by harrionsion book
Hypertension llb explains by harrionsion bookHypertension llb explains by harrionsion book
Hypertension llb explains by harrionsion book
 
symptomatic hypertension
symptomatic hypertensionsymptomatic hypertension
symptomatic hypertension
 
Hypertension presentation
Hypertension presentationHypertension presentation
Hypertension presentation
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension - Approach & Management
Hypertension - Approach & ManagementHypertension - Approach & Management
Hypertension - Approach & Management
 
hypertension-161006095542.pptx
hypertension-161006095542.pptxhypertension-161006095542.pptx
hypertension-161006095542.pptx
 
Blood pressure regulation
Blood pressure regulationBlood pressure regulation
Blood pressure regulation
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension (HTN)
Hypertension (HTN)Hypertension (HTN)
Hypertension (HTN)
 

Dernier

Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 

Dernier (20)

Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 

Hypertension

  • 2.  Basics Understanding of hypertension: . Introduction . Symptoms .Types . Risk factors . Pathophysiology . Classifications . Causes & complications . Work sheet /recap • Treatment : Algorithm • RAAS • Antihypertensive drugs • Compelling Indication for hypertensive drugs • Diabetes and hypertension • CVD risks in CKD • Work sheet/recap
  • 3.  A sustained elevation in arterial blood pressure above the normal value is called hypertension.  Normal value for blood pressure varies greatly from person to person.
  • 4. • Tiredness • Confusion • Vision changes • Angina-like chest pain • Heart failure • Blood in urine • Bleeding nose • Irregular heartbeat etc
  • 5. . Primary hypertension: also called essential hypertension, the cause of this type is unknown. . Secondary hypertension: have specific identified cause for elevated BP that due to any other medical problems or medication. . Pseudo hypertension: Osler’s sign of pseudo hypertension, a falsely elevated BP regarding due to calcification of blood vessel which can not be compressed. . White coat hypertension: A syndrome whereby a patient’s feeling of anxiety in a medical environment results in an abnormally high reading when their blood pressure is measured.
  • 7.  There are two values for blood pressure in a human being. ◦ Systolic blood pressure : Blood pressure recorded during ventricular systole ( contraction of ventricles). ◦ Diastolic blood pressure : Blood pressure recorded during ventricular diastole ( relaxation of ventricle) . For the diagnosis blood pressure should be measured at least on two separate occasions. Continue….
  • 9. Continue…. Pathophysiology of hypertension: Blood pressure = cardiac output x total peripheral resistance • Cardiac output = Hear rate X Stroke volume (cardiac output: the amount of blood that the heart flows in a minute. stroke volume: the amount of blood that heart flows during a cardiac cycle. Cardiac cycle: the sequences of events that occurs when the heart beats)
  • 10.  The National High Blood Pressure Education Program presents the complete Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.  Table below provides a classification of BP for adults aged 18 and older.  The classification is based on the average of 2 or more properly measured, seated BP readings on each of 2 or more office visits.
  • 11. Category SBP (mm Hg) DBP (mm Hg) Normal < 120 and < 80 Pre-hypertension 120-139 or 80-89 Hypertension, Stage-1 140-159 or 90-99 Hypertension, Stage-2 > 160 or > 100
  • 12. Pt age SBP (mm Hg) DBP (mm Hg) >/= 60 yrs < 150 and < 90 < 60 yrs < 140 and <90 < 60 yrs with CKD <140 and <90 < 60 yrs with DM <140 and < 90
  • 14.  The prevalence of hypertension increases with advancing age to point where more than half people aged 60 to 69 years old and approximately three fourths of those aged 70 years and older are affected.  The age-related rise in SBP is primarily responsible for an increase in both incidence and prevalence of hypertension with increasing age.
  • 15.  95% of hypertensive patients have no apparent identifiable cause, hence called primary or essential hypertension.  5% have some underlying cause to account for the hypertension and called secondary hypertension.
  • 16. Renal: related to kidney disease  Acute Renal Failure : Loss of function of kidney over a short period of time.  Chronic Renal Failure: failure of function of kidney over a long time.  Glomerulonephritis : ( inflammation of glomerulus, a structural & functional unit of kidney)
  • 17. Endocrine system:  Cushing Disease: It is a disorder caused by high levels of cortisol (hormone ) in the blood from a variety of causes, including cancer of pituitary gland  Hypothyroidism: low levels of thyroid hormone  Pheochromocytoma : It is a tumour (cancer ) that arises from the centre of the adrenal gland  Primary Hyperaldosteronism : increase secretion of aldosterone
  • 18. Renovascular  Renal artery stenosis ( narrowing of arteries of kidney) Miscellaneous  Pregnancy Induced hypertension  Drug induced
  • 19. Untreated hypertension can develop damage to heart, kidney, retina and brain.  Stroke : Sustained persistent high blood pressure may lead to rupture of an artery in the brain causing brain haemorrhage/stroke ( bleeding )  Retinopathy : Similarly it cause damage to the blood vessels of retina and swelling of retina which may lead to blindness.
  • 20.  Nephropathy : Kidneys are also severely damaged and ultimately may develop renal failure (hypertensive nephropathy).  Myocardial infarction : Accelerates atherosclerosis, which may predispose to development of blood clot in the artery (thrombosis).Thrombosis in the brain or heart ultimately causes brain infract or myocardial infract (heart attack).
  • 21. Summary : Heart damage – MI,CHF Kidney damage – nephropathy Eye damage – retinopathy, loss of vision Blood vessel damage – arteriosclerosis Brain damage - stroke
  • 23.  The relationship between BP and risk of CVD events is continuous, consistent and independent of other risk factors.  Higher the BP, the greater is the chance of heart attack, HF, stroke, and kidney disease.
  • 25.  a) Systolic BP  b ) Diastolic BP  c) Pulse Pressure  d) None of Above
  • 26. Ans :
  • 27.  a) Essential or Primary  b) Secondary  c) Malignant  d) None of Above
  • 28. Ans :
  • 29.  a) Inconsistent  b) Continuous  c) Continuous, consistent & independent  d) None of above
  • 30.  a) <140/90  b) > 140/90  c) < 130/80  d) None of above
  • 33.  Kidney in response to low BP, reduced blood volume or low sodium content release an enzyme, renin  Renin interacts with angiotensinogen to form angiotensin I  Angiotensin I gets converted to angiotensin II with the help of ACE  Angiotensin II causes aldesterone release from kedney,which causes sodium and water retention leading to increase blood volume.  Similarly, angiotensin II causes vasoconstriction.  These effects lead to increase in blood pressure.
  • 34.  Weight reduction  DASH (Dietary approach to stop hypertension) eating plan: diet rich in fruits, vegetables, low fat dairy products with a reduced content of saturated and total fat  Dietary sodium restriction  Physical activity & Moderation of alcohol consumption
  • 36. ACE inhibitors : Enlapril, Ramipril etc.  ACE inhibitors inhibit the conversion of angiotensin I into angiotensin II by inhibiting ACE ( Angiotensin converting enzyme). They blunt the effects mediated by angiotensin II ( like vasoconstriction , release of aldosterone etc.) β blockers : Metoprolol, Bisoprolol etc.  β blockers act by reducing heart rate and myocardial contractility by blocking β1 receptors primarily in the heart.
  • 37. Angiotensin II receptor blockers(ARBs ): Losartan,Telmisartn, Olmesartan etc.  ARBs block the activation of angiotensin II AT1 receptors. Blockade of AT1 receptors directly causes vasodilation, reduces secretion of vasopressin, reduces production and secretion of aldosterone, amongst other actions – the combined effect of which is reduction of blood pressure.
  • 38. Calcium channel blockers: Amlodipine, long acting Nifedipine etc.  Calcium channel blockers work by blocking calcium channels in the heart and in the blood vessels. This prevents calcium levels from increasing as much in the cells when stimulated, leading to less contraction. α1 blockers like Prazosin, Terazosin etc.  α1 blockers act by blocking the alpha1-receptors of vascular smooth muscle, thus preventing the uptake of catecholamine(harmones produced by adrenal gland) by the smooth muscle cells.  This causes vasodilatation and allows blood to flow more easily.
  • 39. Diuretics: Hydrochlorothiazide, Torsemide etc.  Diuretics act by enhanced urinary excretion of sodium , chloride and water. Aldosterone antagonists: Spironolactone, Eplerenone etc.  Aldosterone antagonists act by inhibits the effect of aldosterone by competing for intracellular aldosterone receptors the distal tubule cells. This increases the secretion of water and sodium, while decreasing the excretion of potassium
  • 40.  -adrenergic blockers and diuretics  ACE inhibitors and diuretics  Angiotensin II receptor antagonists and diuretics  Calcium antagonists and ACE inhibitors  Other combinations
  • 41. Compelling Indication : Initial therapy options Heart Failure : THIAZ,BB,ACEI,ARB,ALDO ANT Post myocardial infraction : BB,ACEI,ALDO ANT High CVD risk : THIAZ,BB,ACEI,CCB Diabetes : THIAZ,BB,ACEI,ARB,CCB Chronic kidney disease : ACEI,ARB Recurrent stroke prevention : THIAZ,ACEI
  • 42.  Good therapeutic efficacy.  Longer duration of action.  Permitting once a day dosing.  Cost effective.  Minimal or no adverse effect.  Minimal or no drug interaction.  Should be safe in elderly patients.  Should effectively reduces the consequences of hypertension.
  • 43.  Compelling indications: Hypertension may exist in association with other conditions in which there are compelling indications for use of a particular treatment based on clinical trial data demonstrating benefit of such therapy.  Example: hypertension associated diabetes  In this case, ACEI or ARB should be used as the first line therapy  In this , the drug of first choice is either ACE inhibitor or ARB (angiotensin receptor blocker )
  • 44.  Type 2 diabetes constitutes over 90% of diabetes in the United States and is associated with a 70% to 80% chance of premature death from CVD and stroke.  The concordance of hypertension and diabetes is increased in the population; hypertension is disproportionately higher in diabetics while persons with elevated BP are 2.5 times more likely to develop diabetes within 5 years
  • 45.  The coexistence of hypertension in diabetes is particularly pernicious because of the strong linkage of the 2 conditions with all CVD, stroke, progression of renal disease and diabetic retinopathy.  The United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that each 10 mm Hg decrease in SBP was associated with average reductions in rates of diabetes- related mortality of 15%; myocardial infarction, 11%; and the microvascular complications of retinopathy or nephropathy, 13%.
  • 46.  CVD is the most common cause of death in individuals with CKD, and CKD is itself an independent risk factor for CVD.  The joint recommendations of the American Society of Nephrology and the National Kidney Foundation (NKF) provide useful guidelines for management of hypertensive patients with CKD.  They recommend a goal BP for all CKD patients of <_130/80 mm Hg and a need for more than 1 antihypertensive drug to achieve this goal.
  • 47.  The guidelines indicate that most patients with CKD should receive an ACEI or an ARB in combination with a diuretic and that many will require a loop diuretic( act at the ascending limb of the loop of Henle in the kidney) rather than a thiazide.  In addition, if there is a conflict between the goals of slowing progression of CKD and CVD risk reduction, individual decision- making is recommended, based on risk stratification.
  • 48.  An associated disease with hypertension compels not to use a specific antihypertensive drugs for treatment of hypertension.  For example: bronchial asthma with hypertension is a compelling contraindication for β blocker.
  • 49.  It is not a curable but a controllable disease  Onset is generally at age of 40 or more.  Has strong association with atherosclerosis.  Familial tendency is also known.  If not treated, it goes on progressing.  Untreated hypertension can develop damage to heart, kidney, retina and brain.  Treatment can prevent these complications.
  • 51.  a) DASH Diet  b) Weight reduction  c) Physical activity  d) All above
  • 52. Ans :
  • 53.  a) Calcium channel blockers  b) ACEI  c) ARB  d) b & c
  • 54. Ans :
  • 55.  a) Calcium channel blockers  b) ARBs  c) Non-selective 1 –blockers  d) None of above